Core Viewpoint - The company plans to use its capital reserve to offset accumulated losses, aiming to improve its financial condition and enhance investor returns [4][5][34]. Company Overview - The company, Leshan Electric Power Co., Ltd., reported a negative retained earnings of CNY 531,917,431.97 as of December 31, 2024, primarily due to the bankruptcy of its former subsidiaries [4][5]. - The company will not distribute profits or increase capital reserves in 2025 [1]. Financial Data - As of the end of the reporting period, the company had a surplus reserve of CNY 123,023,162.30 and a capital reserve of CNY 1,378,055,899.65 [4][5]. - The total amount to be used for offsetting losses is CNY 531,917,431.97, which includes the surplus reserve and part of the capital reserve [5]. Important Matters - The board of directors and the supervisory board have approved the proposal to use the capital reserve to offset losses, which will require shareholder approval [7][34]. - The company has reported that it will not change its fundraising projects [15]. Fundraising and Usage - The company raised CNY 199,999,996.59 through a simplified procedure for issuing A-shares, with a net amount of CNY 198,133,651.71 after deducting issuance costs [9][10]. - As of June 30, 2025, the company has used CNY 29,291,740.10 of the raised funds, leaving a balance of CNY 169,322,544.79 [10][14]. Management of Funds - The company has established a three-party supervision agreement for the management of raised funds, ensuring compliance with regulatory requirements [11].

Company Overview - The company did not change its controlling shareholder or actual controller during the reporting period [4][3] - The company plans not to distribute cash dividends or issue bonus shares [3] Financial Data and Key Indicators - The company raised a total of RMB 132,254,085.60 through the issuance of 39,361,335 shares at a price of RMB 3.36 per share, with a net amount of RMB 124,907,065.46 after deducting issuance costs [6][7] - As of June 30, 2025, the balance in the fundraising account was RMB 33,989,185.06 [7] Important Events - On April 23, 2023, the company approved a proposal to issue shares to specific targets through a simplified procedure [4] - The company received approval from the China Securities Regulatory Commission for the stock issuance on August 20, 2024 [4] Fundraising Management - The company established a special account for fundraising management and signed a tripartite supervision agreement with the bank and the sponsor [9] - The company revised its fundraising management system to comply with relevant laws and regulations [8] Fund Usage - The company has not changed the implementation location or method for fundraising investment projects as of June 30, 2025 [11][16] - There were no cases of using idle fundraising to replace prior investments [12] Board and Supervisory Meetings - The company held a board meeting on August 28, 2025, where the half-year report and fundraising usage report were approved unanimously [21][19] - The company plans to hold its first extraordinary shareholders' meeting on September 16, 2025 [25]

Group 1 - The company held its 23rd meeting of the 4th Board of Directors on August 29, 2025, to discuss the 2025 semi-annual report and related matters [4][5] - The Board confirmed that the semi-annual report was prepared in accordance with relevant regulations and accurately reflects the company's operational and financial status [5][14] - The company has not proposed any profit distribution or capital increase plans during this reporting period [2][3] Group 2 - The company has approved the special report on the storage and use of raised funds, confirming that funds are stored in dedicated accounts and used for specified purposes [7][16] - As of June 30, 2025, the company has utilized approximately 354.83 million yuan of the raised funds, with a remaining balance of about 229,911.29 yuan [21] - The company has engaged in cash management with idle raised funds, investing up to 100 million yuan in low-risk financial products, generating interest income of 491,246.54 yuan [27][28]

Core Viewpoint - The company has released its 2025 semi-annual report, which includes financial data and the status of fundraising activities, ensuring compliance with regulatory requirements [1][4][11]. Company Overview - The company is identified as 中安科 (Zhong An Ke), with the stock code 600654 [1]. - The report emphasizes the importance of reviewing the full semi-annual report for a comprehensive understanding of the company's performance and future plans [1]. Financial Data - The company raised a total of approximately RMB 952.99 million through a non-public offering of 131,994,459 shares at an issue price of RMB 7.22 per share [11]. - After deducting issuance costs of about RMB 19.06 million, the net proceeds amounted to approximately RMB 933.94 million [11]. - As of June 30, 2025, the company had invested approximately RMB 902.66 million of the raised funds, with a remaining balance of RMB 59,951.80 [12]. Board Meeting - The 12th Board of Directors held its fifth meeting on August 29, 2025, with all nine directors present, and the meeting adhered to legal and procedural requirements [3][6]. - The board approved the semi-annual report and the special report on the use of raised funds, confirming that these documents had been reviewed by the audit committee prior to the meeting [4][7]. Fundraising Management - The company has established a management framework for the raised funds, ensuring compliance with relevant laws and regulations [13]. - A four-party supervision agreement was signed with banks to manage the raised funds, ensuring proper oversight [14]. Fund Usage - No funds were used to replace pre-invested capital in the first half of 2025, and there were no investments made with idle funds during this period [16][18]. - The company had previously approved the temporary use of RMB 37 million of idle funds to supplement working capital, but due to account freezes, the funds were not returned as scheduled [17][21]. Issues and Compliance - The company has been actively addressing issues related to the temporary use of idle funds and is exploring solutions to resolve historical problems and related litigation [21]. - The company asserts that all disclosed information regarding the use of raised funds is timely, truthful, accurate, and complete, with no violations of regulatory requirements [21].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000157 证券简称：中联重科 公告编号：2025－044号 一、重要提示 本半年度报告摘要来自半年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投 资者应当到证监会指定媒体仔细阅读半年度报告全文。 所有董事均已出席了审议本报告的董事会会议。 非标准审计意见提示 □适用 √不适用 董事会审议的报告期利润分配预案或公积金转增股本预案 √适用 □不适用 是否以公积金转增股本 □是 √否 公司经本次董事会审议通过的利润分配预案为：以实施2025年中期利润分配时股权登记日的总股本为基 数，向全体股东每10股派发现金红利2.00元（含税），送红股0股（含税），不以公积金转增股本。 董事会决议通过的本报告期优先股利润分配预案 □适用 √不适用 二、公司基本情况 1、公司简介 ■ 2、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 √否 ■ 3、公司股东数量及持股情况 持股5%以上股东、前10名股东及前10名无限售流通股股东参与转融通业务出借股份情况 公司报告期控股股东未发生变更。 实际控制人报告期内变更 □适用 √不适 ...

Core Viewpoint - The company has released its 2025 semi-annual report, which includes details on financial performance, profit distribution, and the management of raised funds [3][9][30]. Group 1: Company Overview - The company is named Nanjing Pharmaceutical Co., Ltd., with stock code 600713 and bond code 110098 [5]. - The board of directors and supervisory board confirm the authenticity and completeness of the report [1][28]. Group 2: Financial Data - The company did not distribute profits during the reporting period, but plans to distribute a cash dividend of 1.70 yuan per 10 shares, totaling approximately 222.47 million yuan [3]. - The total amount raised from the issuance of convertible bonds was approximately 1.08 billion yuan, with a net amount of about 1.07 billion yuan after deducting issuance costs [13]. Group 3: Fund Management - As of June 30, 2025, the balance of the raised funds was approximately 124.10 million yuan [14]. - The company has established special accounts for the management of raised funds, ensuring compliance with relevant regulations [15]. - The company has not used idle raised funds to temporarily supplement working capital [18]. Group 4: Board and Supervisory Meetings - The board of directors held its third meeting on August 28, 2025, where all proposals were approved unanimously [8][9]. - The supervisory board also approved the semi-annual report and the special report on the management of raised funds, with no dissenting votes [30][31].

Core Viewpoint - The company has released its 2025 semi-annual report, which includes financial performance, management of raised funds, and plans for future development [1][10][32]. Group 1: Company Overview - The company is Qingdao Impulse Health Technology Co., Ltd., with stock code 002899 [1]. - The company has not changed its controlling shareholder or actual controller during the reporting period [5][6]. Group 2: Financial Data and Performance - The company reported a total fundraising amount of RMB 481.5 million from its initial public offering, with a net amount of RMB 433.2 million after deducting issuance costs [33]. - In 2022, the company raised RMB 386.1 million through a private placement, with a net amount of RMB 379.7 million after costs [34]. Group 3: Fund Management and Usage - The company has established specific accounts for managing raised funds, ensuring compliance with regulations [36]. - As of June 30, 2025, the company has detailed the usage of raised funds in its reports, confirming that all funds have been used according to the planned projects [46]. Group 4: Board and Supervisory Meetings - The fourth board meeting of 2025 was held on August 29, where the semi-annual report and the special report on the management of raised funds were approved unanimously [20][22]. - The supervisory board also confirmed that the report accurately reflects the company's situation without any misleading statements [11]. Group 5: Upcoming Shareholder Meeting - The company will hold its first extraordinary general meeting of 2025 on September 16, 2025, to discuss various proposals, including changes to the company’s registered address and amendments to the articles of association [52][75].

Fundraising Overview - The company raised a total of RMB 302,495.13 million by issuing 19,851,367 shares at a price of RMB 152.38 per share, with a net amount of RMB 273,079.07 million after deducting issuance costs [1][19] - As of June 30, 2025, the balance in the fundraising special account was RMB 16,199.4 million, with RMB 94,300 million used for cash management and RMB 57,497.87 million invested in projects [2] Fund Management - The company has established a fundraising management system in compliance with relevant laws and regulations, ensuring dedicated storage and management of the raised funds [3] - A tripartite supervision agreement has been signed with the sponsor and banks holding the fundraising account to ensure proper oversight [4] Fund Usage - The company has not used idle funds for temporary working capital as of June 30, 2025 [6] - The company has approved the use of up to RMB 180,000 million of idle funds for cash management, investing in low-risk financial products with a maturity of no more than 12 months [7][8] - As of June 30, 2025, the balance of idle funds under cash management was RMB 94,300 million [9] Project Investment - The company has not made any pre-investments or replacements for fundraising projects during the reporting period [5] - The company has replaced RMB 10,979.33 million of its own funds with raised funds for project payments [12] - All fundraising projects, including the X-ray source industrialization project and R&D center construction project, have been completed with no surplus funds [12] Changes in Fundraising Projects - There have been no changes or transfers of fundraising projects as of June 30, 2025 [13][14] Compliance and Disclosure - The company has complied with disclosure requirements regarding the management and usage of raised funds, with no violations reported [15]

证券代码：688173 证券简称：希荻微 公告编号：2025-068 希荻微电子集团股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《上市公司募集资金监管规则》 （以下简称" 《募集资金监管规则》"）以 及《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》（以下 简称"《规范运作》"）等相关规定，希荻微电子集团股份有限公司（以下简称"公 司"）就 2025 年半年度募集资金存放与使用情况作如下专项报告： 一、募集资金基本情况 （一）实际募集资金的金额及到账情况 经中国证券监督管理委员会《关于同意广东希荻微电子股份有限公司首次公 开发行股票注册的批复》 （证监许可〔2021〕3934 号）同意注册，并经上海证券 交易所同意，公司向社会公众公开发行人民币普通股 4,001 万股，每股面值人民 币 1.00 元，每股发行价为人民币 33.57 元，募集资金总额为人民币 134,313.57 万元，扣除发行费用后的募集资金净额为人民币 122,140.85 万元。上述募集资金 已全部到位，业经普华 ...

Summary of Key Points Core Viewpoint The report provides an overview of the fundraising activities and the utilization of raised funds by Hainan Huluwa Pharmaceutical Group Co., Ltd. for the first half of 2025, highlighting the total amount raised, expenses incurred, and the allocation of funds to various projects. Fundraising Basic Situation - The company raised a total of RMB 208,119,000.00 by issuing 40,100,000 shares at RMB 5.19 per share, with net proceeds amounting to RMB 173,119,000.00 after deducting underwriting fees of RMB 35,000,000.00 [1][2]. - The funds were deposited into a regulatory account managed by the lead underwriter, CITIC Securities Co., Ltd. [1]. Fundraising Usage and Balance - As of June 30, 2025, the total amount of raised funds was RMB 208,119,000.00, with total expenses of RMB 57,079,347.77, resulting in a net amount of RMB 151,039,652.23 [2]. - The remaining balance of the raised funds at the end of the period was RMB 11,878,482.50 after accounting for various expenditures and interest income [2][4]. Fund Management and Storage - The company established a dedicated account for the management of raised funds, adhering to relevant regulations and guidelines to ensure proper usage and protection of investor interests [2][3]. - A tripartite supervision agreement was signed with the banks and the underwriter to clarify the rights and obligations of all parties involved [2][3]. Project Adjustments and Fund Allocation - The company adjusted the implementation of the "Marketing System Construction and Brand Promotion Project" to be managed by its wholly-owned subsidiary, Hainan Huluwa Pharmaceutical Co., Ltd. [3]. - The company decided to reallocate funds from the "Pediatric Drug Research Project" to other urgent drug research projects due to delays in the original project [10][11]. Financial Performance and Future Outlook - The company reported that the fundraising projects do not directly generate economic benefits, making it challenging to assess their individual performance [6][11]. - The long-term benefits of the drug research projects are expected to enhance the company's core competitiveness and market presence [6][7]. Compliance and Disclosure - The company confirmed compliance with all relevant laws and regulations regarding the use of raised funds and timely disclosure of information [12][13]. - There were no violations in the use of raised funds, and all disclosed information accurately reflects the company's financial activities [12].